Eli Lilly is gearing up to launch its Alzheimer’s drug for use in early-stage patients after receiving US approval on Tuesday, offering the medicine at a steep premium to a competitor as it claims it is more efficient.
The drug — to be sold under the brand name Kisunla — will enter the US market a year after the first fully approved medicine to treat the neurodegenerative disease, developed jointly by pharmaceutical groups Biogen and Eisai, was launched.
The drug slows the development of Alzheimer’s, which causes memory loss, dementia and other cognitive impairment. An estimated 7mn patients suffer from Alzheimer’s in the US. More than 1mn early-stage patients will be eligible for Eli Lilly’s drug.
您已閱讀20%（705字），剩余80%（2796字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專(zhuān)屬服務(wù)。